查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082125

免疫腫瘤學檢測市場：按技術、生物標記、療法、檢體類型、應用、最終用戶和適應症分類——2026-2032年全球市場預測

Immuno Oncology Assays Market by Technology Type, Biomarker Type, Therapy Type, Sample Type, Application, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫腫瘤學檢測市場將成長至 231.6 億美元，複合年成長率為 15.71%。

主要市場統計數據
基準年 2025 83.3億美元
預計年份：2026年 95.7億美元
預測年份 2032 231.6億美元
複合年成長率 (%) 15.71%

免疫腫瘤學檢測在癌症治療從基於腫瘤類型的治療轉向基於生物標記的治療中發揮核心作用。這些檢測支持治療方案的選擇、患者分層、治療反應監測以及免疫查核點抑制劑、細胞療法、雙特異性抗體、癌症疫苗和新型聯合治療的轉化研究。關鍵檢測類別包括PD-L1免疫組織化學、微衛星不穩定性及錯配修復檢測、腫瘤突變負荷評估、次世代定序定序、流式細胞技術、細胞激素和免疫譜分析、循環腫瘤DNA分析，以及日益重要的太空生物學和多重螢光平台。

這項需求源自於現有的臨床證據，這些證據顯示免疫生物學標記會影響癌症治療的適用標準、預期療效和抗藥性模式。監管機構也在加強伴隨診斷和檢驗的檢測流程的作用，尤其是在藥物附加檔中需要進行生物標記驗證的情況下。隨著癌症治療研發管線的不斷擴展，檢測方法開發商、診斷實驗室、製藥公司和醫療保健系統都在優先考慮分析有效性、臨床效用、報告時間、互通性和醫保報銷相容性。

對於決策者而言，免疫腫瘤學檢測的願景不再局限於單一分析測試。競爭優勢越來越依賴整合組織、血液、基因組、蛋白質體學和免疫細胞數據的整合平台，將這些數據轉化為臨床適用的見解，同時維持實際臨床應用所需的品質標準。

免疫腫瘤學檢測領域的變革性變化

精準醫療、分散式檢查以及日益複雜的治療研發管線正在重塑腫瘤免疫學檢測的模式。儘管傳統的單標記檢測仍然重要，尤其是在PD-L1和MSI/MMR檢測方面，但業界正轉向更廣泛、多參數和縱向的方法，以更全面地了解腫瘤與免疫系統的相互作用。這種轉變得益於次世代定序、數位病理學、高參數流式細胞技術、液態生物檢體和空間分析技術在臨床研究和先進診斷環境中的日益普及。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在對免疫腫瘤學檢測方法的開發、檢驗和臨床解讀等各個領域產生累積影響。在數位病理學領域，AI 驅動的影像分析能夠量化免疫細胞浸潤、腫瘤百分比評分 (TPS)、複合陽性評分 (CPS)，並分析腫瘤微環境內的空間關係。當人工解讀容易出現差異或生物標記閾值影響治療決策時，這些功能尤其重要。

關鍵區域洞察

北美地區仍然是腫瘤免疫學檢測領域的領先地區，這得益於該地區癌症藥物研發公司、參考實驗室、大學附屬癌症中心、臨床試驗網路以及完善的伴隨診斷路徑的集中。美國透過在免疫療法領域進行廣泛的臨床試驗、在腫瘤學中廣泛應用次世代定序以及基於指南的生物標記檢測，極大地推動了該地區免疫腫瘤學檢測技術的發展。加拿大則透過公共資助的癌症計畫、分子診斷網路以及日益成長的跨省精準癌症診療一體化意識，為該領域做出了貢獻。

主要群體分析

七國集團（G7）憑藉其高昂的醫療支出、成熟的監管體系、領先的腫瘤研究生態系統和尖端的學術癌症網路，對免疫腫瘤學檢測標準有著舉足輕重的影響。這些國家往往是伴隨診斷、多重檢測、液態生物檢體和人工智慧病理診斷工具的早期採用者，使其成為經臨床檢驗的免疫腫瘤學檢測平台的重要市場。

主要國家的關鍵見解

美國是免疫腫瘤學檢測領域最具影響力的國家，這得益於FDA批准的伴隨診斷、廣泛的腫瘤臨床試驗、強大的參考檢查室網路以及基於指南的分子檢測的廣泛應用。加拿大緊隨其後，在其以實證醫學為基礎的公共醫療體系中，各省的醫保報銷方案和癌症機構的優先事項會影響生物標記檢測的可及性。墨西哥正透過私立醫院和專科中心拓展精準腫瘤學，而巴西則憑藉其大規模的癌症患者群體、活躍的私營診斷行業和不斷擴大的臨床研究基礎，代表著拉丁美洲巨大的市場機會。

為行業領導者提供的實用建議

產業領導者應優先考慮兼具明確臨床效用與可擴展檢查室經濟性的檢測組合。尤其是在癌症治療逐漸轉向免疫療法聯合治療、抗藥性監測和患者長期管理的情況下，支持多種生物標記、檢體類型和治療層級的平台比單一檢測更具優勢。

調查方法

本執行摘要基於一套系統的調查方法，該方法整合了二手研究、市場情報、監管檢驗和專家解釋。資訊來源包括公開的監管文件、臨床實踐指南、同行評審的癌症文獻、產品標籤、診斷技術更新、臨床試驗註冊資訊、保險報銷材料和醫療保健政策文件。

結論

隨著治療決策越來越依賴可靠的生物標記證據，免疫腫瘤學檢測在現代癌症治療中變得至關重要。該領域正從單一標記檢測擴展到整合免疫分析、多體學分析、液態生物檢體、數位病理學和人工智慧輔助解讀。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：免疫腫瘤學檢測市場：依技術類型分類

  • 流式細胞技術
  • 免疫檢測
  • 質譜流式細胞儀
  • 次世代定序

第8章：免疫腫瘤學檢測市場：依生物標記類型分類

  • 蛋白質生物標記
  • 基因生物標記
  • 轉錄組生物標記
  • 細胞生物標記
  • 表觀遺傳生物標記

第9章：免疫腫瘤學檢測市場：依治療類型分類

  • 免疫查核點抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞療法
    • CAR-T細胞療法
    • TCR-T細胞療法
  • 癌症疫苗
  • 溶瘤病毒療法
  • 雙特異性抗體

第10章：免疫腫瘤學檢測市場：依樣本類型分類

  • 血
  • 細胞株
  • 組織

第11章：免疫腫瘤學檢測市場：依應用領域分類

  • 生物標記發現
  • 伴隨診斷
  • 細胞激素分析
  • 免疫療法
  • 腫瘤微環境分析

第12章：免疫腫瘤學檢測市場：依最終用戶分類

  • 學術研究機構
    • 研究機構
    • 大學
  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物技術

第13章：免疫腫瘤學檢測市場：依適應症分類

  • 乳癌
  • 血癌
  • 肺癌
  • 黑色素瘤

第14章：免疫腫瘤學檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：免疫腫瘤學檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：免疫腫瘤學檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • Abcam PLC
  • ACROBiosystems
  • Adaptive Biotechnologies Corporation
  • AdipoGen Life Sciences, Inc.
  • Advanced Cell Diagnostics, Inc.
  • Agilent Technologies Inc.
  • Akoya Biosciences Inc.
  • Aurigene Pharmaceutical Services Limited
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Biocare Medical, LLC
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc.
  • Illumina Inc.
  • Invivoscribe Inc.
  • Merck KGaA
  • Meso Scale Diagnostics LLC
  • Myriad Genetics Inc.
  • NanoString Technologies by Bruker Corp.
  • NeoGenomics Laboratories
  • PerkinElmer Inc.
  • Qiagen NV
  • Quanterix Corporation
  • Siemens Healthineers AG
  • Standard BioTools Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market is projected to grow by USD 23.16 billion at a CAGR of 15.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.33 billion
Estimated Year [2026] USD 9.57 billion
Forecast Year [2032] USD 23.16 billion
CAGR (%) 15.71%

Immuno-oncology assays are central to the shift from tumor-type prescribing toward biomarker-guided cancer care. These tests support therapy selection, patient stratification, response monitoring, and translational research across immune checkpoint inhibitors, cell therapies, bispecific antibodies, cancer vaccines, and emerging combination regimens. Core assay categories include PD-L1 immunohistochemistry, microsatellite instability and mismatch repair testing, tumor mutational burden assessment, next-generation sequencing panels, flow cytometry, cytokine and immune profiling assays, circulating tumor DNA analysis, and increasingly, spatial biology and multiplex immunofluorescence platforms.

Demand is anchored in established clinical evidence showing that immune biomarkers can influence eligibility, expected response, and resistance patterns for oncology therapeutics. Regulatory agencies have also reinforced the role of companion diagnostics and validated laboratory workflows, particularly where drug labels require biomarker confirmation. As oncology pipelines continue to expand, assay developers, diagnostic laboratories, pharmaceutical sponsors, and healthcare systems are prioritizing analytical validity, clinical utility, turnaround time, interoperability, and reimbursement alignment.

For decision-makers, the immuno-oncology assays landscape is no longer limited to single-analyte testing. Competitive advantage increasingly depends on integrated platforms that combine tissue, blood, genomic, proteomic, and immune-cell data into clinically actionable insights while maintaining the quality standards required for real-world adoption.

Transformative Shifts in the Immuno-Oncology Assay Landscape

The immuno-oncology assays landscape is being reshaped by the convergence of precision medicine, decentralized testing, and increasingly complex therapeutic pipelines. Traditional single-marker assays remain important, especially for PD-L1 and MSI/MMR testing, but the industry is moving toward broader, multiplexed, and longitudinal approaches that capture tumor-immune interactions more comprehensively. This transition is supported by the increased use of next-generation sequencing, digital pathology, high-parameter flow cytometry, liquid biopsy, and spatial analysis technologies in both clinical research and advanced diagnostic settings.

Pharmaceutical development is also changing the assay value chain. As immunotherapy combinations and biomarker-defined indications grow, sponsors require assays that can support patient enrichment, pharmacodynamic monitoring, resistance profiling, safety evaluation, and regulatory submissions. This has increased demand for co-development models between biopharma companies, diagnostic manufacturers, central laboratories, hospital networks, and contract research organizations.

Health systems are simultaneously pressing for evidence that assays improve outcomes and justify costs. Reimbursement decisions increasingly depend on demonstrated clinical utility, guideline inclusion, laboratory accreditation, and reliable turnaround times. As a result, the most resilient participants are those that can balance innovation with standardization, interoperability, quality assurance, and payer-relevant evidence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across immuno-oncology assay development, validation, and clinical interpretation. In digital pathology, AI-enabled image analysis can support quantification of immune-cell infiltration, tumor proportion scoring, combined positive scoring, and spatial relationships within the tumor microenvironment. These capabilities are particularly relevant where manual interpretation is variable and where biomarker thresholds influence treatment decisions.

AI is also accelerating multi-omics integration. Machine learning models can evaluate genomic alterations, expression signatures, histopathology images, radiology data, laboratory values, and clinical outcomes to identify composite biomarkers that may outperform single-analyte assays. In research settings, these methods are being used to explore mechanisms of response, immune escape, toxicity risk, and minimal residual disease dynamics, while regulated clinical deployment continues to require transparent validation, bias assessment, auditability, and quality management.

The near-term opportunity is not replacing laboratory expertise but augmenting it. AI can reduce analytical bottlenecks, improve consistency, prioritize complex cases for review, and support trial enrollment by matching patients to biomarker-defined protocols. Industry leaders that invest in curated datasets, explainable algorithms, regulatory-grade documentation, cybersecurity controls, and responsible data governance will be best positioned to convert AI from an experimental tool into a trusted component of immuno-oncology diagnostics.

Key Regional Insights

North America remains a leading region for immuno-oncology assays due to its concentration of oncology drug developers, reference laboratories, academic cancer centers, clinical trial networks, and established companion diagnostic pathways. The United States drives much of the region's adoption through extensive immunotherapy trial activity, broad use of next-generation sequencing in oncology, and guideline-based biomarker testing. Canada contributes through publicly funded cancer programs, molecular diagnostics networks, and growing interest in harmonized access to precision oncology across provinces.

Europe is shaped by strong clinical research infrastructure, national health technology assessment processes, and the European Union's evolving regulatory framework for in vitro diagnostics. Germany, France, Italy, Spain, and the United Kingdom continue to support adoption through specialist oncology centers and biomarker-driven care pathways, although reimbursement timing, laboratory capacity, and regional implementation differ by country. The region's emphasis on evidence generation, laboratory quality, and clinical governance is encouraging greater standardization across immunohistochemistry, next-generation sequencing, and molecular pathology workflows.

Asia-Pacific is one of the most dynamic regions, supported by large cancer patient populations, rising healthcare investment, expanding clinical trial participation, and strong biotechnology capabilities in China, Japan, South Korea, Australia, India, and ASEAN markets. Japan and South Korea are notable for advanced diagnostics infrastructure and established oncology care systems, while China and India are scaling oncology testing capacity to meet substantial demand. Latin America, led by Brazil and Mexico, is progressing through private-sector adoption, oncology network expansion, and increasing awareness of precision medicine, though uneven reimbursement and infrastructure constraints remain important barriers.

The Middle East is gaining momentum as Gulf countries invest in oncology centers, genomic medicine initiatives, accredited laboratory services, and medical tourism strategies. GCC healthcare systems are prioritizing high-quality diagnostics and partnerships with international clinical and laboratory networks. Africa remains an emerging opportunity where cancer burden is increasing, but access to advanced immuno-oncology assays is constrained by pathology workforce shortages, affordability, sample logistics, and laboratory infrastructure gaps. Across Africa, targeted partnerships, capacity building, external quality assessment, and regional reference testing models are essential to broaden access.

Key Group Insights

The G7 markets exert significant influence on immuno-oncology assay standards because they combine high healthcare spending, mature regulatory systems, major oncology research ecosystems, and leading academic cancer networks. These countries are often early adopters of companion diagnostics, multiplex assays, liquid biopsy, and AI-enabled pathology tools, making them important launch environments for clinically validated immuno-oncology testing platforms.

The European Union is advancing a more structured diagnostics environment through harmonized in vitro diagnostic rules, cross-border research programs, and increasing emphasis on data governance. While implementation complexity can challenge smaller developers and laboratories, the EU's focus on analytical performance, clinical evidence, traceability, and post-market oversight supports long-term confidence in oncology assay quality. NATO member markets overlap substantially with high-income healthcare systems and are increasingly attentive to resilient supply chains, cybersecurity for health data, continuity of critical diagnostics, and secure cross-border health infrastructure.

BRICS countries are strategically important because they represent large patient populations, expanding domestic diagnostics capacity, and growing participation in oncology research. China and India are particularly important for scale and clinical trial activity, while Brazil and South Africa offer regional reference points for broader market access and laboratory network development. ASEAN is developing as a heterogeneous but high-potential group, with Singapore acting as a biomedical and clinical research hub and countries such as Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expanding oncology care capacity at different speeds.

The GCC is emerging as a premium diagnostics group supported by government investment in specialized healthcare, national genomics programs, accredited hospitals, and partnerships with international medical institutions. Adoption is strongest where reimbursement, laboratory accreditation, specialist oncology services, and centralized procurement are aligned. Across all groups, the strongest opportunities will come from localized evidence, regionally appropriate pricing, regulatory preparedness, and partnerships that address infrastructure, workforce, and access realities.

Key Country Insights

The United States is the most influential country environment for immuno-oncology assays, supported by FDA-cleared companion diagnostics, extensive oncology trials, strong reference laboratory networks, and broad adoption of guideline-supported molecular testing. Canada follows with an evidence-driven public healthcare environment, where provincial reimbursement and cancer agency priorities influence access to biomarker testing. Mexico is expanding precision oncology through private hospitals and specialist centers, while Brazil is the leading Latin American opportunity due to its large oncology population, active private diagnostics sector, and growing clinical research base.

In Europe, the United Kingdom benefits from national genomics initiatives, strong academic cancer centers, and structured evaluation of new diagnostics. Germany has one of the region's strongest molecular pathology and reimbursement environments, while France supports precision oncology through national cancer strategies and centralized expertise. Italy and Spain show increasing demand for next-generation sequencing and immunotherapy-related testing through hospital networks and regional oncology programs. Russia maintains scientific and clinical oncology capacity, but market access can be affected by procurement complexity, geopolitical constraints, and technology availability.

China is a major growth engine because of its large cancer burden, expanding domestic diagnostics capabilities, and increasing immuno-oncology drug development. India offers substantial long-term potential as oncology infrastructure, private diagnostics networks, clinical trial participation, and awareness of biomarker testing expand, although affordability and equitable access remain key constraints. Japan is a mature precision oncology market with strong regulatory pathways, high-quality laboratory systems, and adoption of companion diagnostics. South Korea combines advanced hospital infrastructure, biotechnology innovation, and digital health readiness, making it an important market for next-generation assays. Australia contributes through strong cancer research, clinical trial participation, public health programs, and public-private adoption of molecular diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay portfolios that connect clear clinical utility with scalable laboratory economics. Platforms that support multiple biomarkers, sample types, and therapy classes are better positioned than isolated tests, particularly as oncology care moves toward combination immunotherapy, resistance monitoring, and longitudinal patient management.

Companies should invest early in regulatory strategy, payer evidence, and guideline alignment. Analytical validation alone is not sufficient; successful commercialization requires proof that testing improves treatment selection, reduces uncertainty, or supports measurable healthcare value. Developers should also design studies that reflect real-world specimen quality, diverse patient populations, pre-analytical variability, and practical workflow constraints.

Strategic partnerships will be essential. Diagnostic innovators should collaborate with biopharma sponsors for companion diagnostic development, with health systems for implementation evidence, and with technology providers for AI-enabled interpretation and data integration. In emerging markets, local partnerships should focus on workforce training, external quality assessment, sample logistics, and hub-and-spoke laboratory models.

Finally, leaders should build trusted data infrastructure. Secure, interoperable, and well-annotated datasets will determine future competitiveness in AI-assisted immuno-oncology assays. Organizations that combine scientific credibility, regulatory discipline, responsible data governance, and clinically meaningful innovation will be best placed to support sustainable adoption.

Research Methodology

This executive summary is developed using a structured research methodology that integrates secondary research, market intelligence synthesis, regulatory review, and expert interpretation. Sources considered include public regulatory documents, clinical practice guidelines, peer-reviewed oncology literature, product labeling, diagnostic technology updates, clinical trial registries, reimbursement references, and healthcare policy materials.

The analysis evaluates immuno-oncology assay demand across technology type, clinical use case, end-user environment, therapeutic relevance, biomarker category, sample type, and geographic adoption conditions. Particular attention is given to companion diagnostic pathways, biomarker testing standards, reimbursement dynamics, laboratory infrastructure, quality accreditation, and evidence requirements for clinical implementation.

Insights are triangulated across multiple information categories to reduce reliance on any single source. The methodology emphasizes verified and publicly supportable findings, avoids unsupported market claims, and prioritizes practical implications for diagnostics manufacturers, pharmaceutical sponsors, clinical laboratories, investors, healthcare providers, and policy stakeholders.

Conclusion

Immuno-oncology assays are becoming indispensable to modern cancer care as therapeutic decisions increasingly depend on reliable biomarker evidence. The field is expanding from single-marker testing toward integrated immune profiling, multi-omics analysis, liquid biopsy, digital pathology, and AI-supported interpretation.

Adoption is strongest where clinical evidence, regulatory readiness, reimbursement support, laboratory capacity, and specialist oncology infrastructure align. North America, Europe, and advanced Asia-Pacific markets remain at the forefront, while Latin America, the Middle East, and Africa present important expansion opportunities that require localized access strategies and capacity-building partnerships.

The next phase of competition will be defined by clinically validated innovation. Organizations that deliver accurate, scalable, reimbursable, interoperable, and data-rich immuno-oncology assays will help accelerate precision oncology while strengthening their position in a rapidly evolving diagnostics ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immuno Oncology Assays Market, by Technology Type

  • 7.1. Flow Cytometry
  • 7.2. Immunoassay
  • 7.3. Mass Cytometry
  • 7.4. Next Generation Sequencing

8. Immuno Oncology Assays Market, by Biomarker Type

  • 8.1. Protein Biomarkers
  • 8.2. Genomic Biomarkers
  • 8.3. Transcriptomic Biomarkers
  • 8.4. Cellular Biomarkers
  • 8.5. Epigenetic Biomarkers

9. Immuno Oncology Assays Market, by Therapy Type

  • 9.1. Immune Checkpoint Inhibitors
    • 9.1.1. PD-1 Inhibitors
    • 9.1.2. PD-L1 Inhibitors
  • 9.2. Cell Therapies
    • 9.2.1. CAR-T Cell Therapies
    • 9.2.2. TCR-T Cell Therapies
  • 9.3. Cancer Vaccines
  • 9.4. Oncolytic Virus Therapies
  • 9.5. Bispecific Antibodies

10. Immuno Oncology Assays Market, by Sample Type

  • 10.1. Blood
  • 10.2. Cell Lines
  • 10.3. Tissue

11. Immuno Oncology Assays Market, by Application

  • 11.1. Biomarker Discovery
  • 11.2. Companion Diagnostics
  • 11.3. Cytokine Analysis
  • 11.4. Immune Monitoring
  • 11.5. Tumor Microenvironment Analysis

12. Immuno Oncology Assays Market, by End User

  • 12.1. Academic And Research Institutes
    • 12.1.1. Research Institutes
    • 12.1.2. Universities
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals And Clinics
  • 12.4. Pharmaceutical And Biotech

13. Immuno Oncology Assays Market, by Indication

  • 13.1. Breast Cancer
  • 13.2. Hematologic Cancers
  • 13.3. Lung Cancer
  • 13.4. Melanoma

14. Immuno Oncology Assays Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Immuno Oncology Assays Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno Oncology Assays Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. Abcam PLC
  • 18.3. ACROBiosystems
  • 18.4. Adaptive Biotechnologies Corporation
  • 18.5. AdipoGen Life Sciences, Inc.
  • 18.6. Advanced Cell Diagnostics, Inc.
  • 18.7. Agilent Technologies Inc.
  • 18.8. Akoya Biosciences Inc.
  • 18.9. Aurigene Pharmaceutical Services Limited
  • 18.10. Becton Dickinson and Company
  • 18.11. Bio-Rad Laboratories Inc.
  • 18.12. Biocare Medical, LLC
  • 18.13. Caris Life Sciences, Inc.
  • 18.14. Danaher Corporation
  • 18.15. F. Hoffmann-La Roche AG
  • 18.16. Guardant Health Inc.
  • 18.17. Illumina Inc.
  • 18.18. Invivoscribe Inc.
  • 18.19. Merck KGaA
  • 18.20. Meso Scale Diagnostics LLC
  • 18.21. Myriad Genetics Inc.
  • 18.22. NanoString Technologies by Bruker Corp.
  • 18.23. NeoGenomics Laboratories
  • 18.24. PerkinElmer Inc.
  • 18.25. Qiagen N.V.
  • 18.26. Quanterix Corporation
  • 18.27. Siemens Healthineers AG
  • 18.28. Standard BioTools Inc.
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MASS CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MASS CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MASS CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELLULAR BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELLULAR BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELLULAR BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EPIGENETIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EPIGENETIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EPIGENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAR-T CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAR-T CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAR-T CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TCR-T CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TCR-T CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TCR-T CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL LINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL LINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL LINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYTOKINE ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOKINE ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYTOKINE ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL UNIVERSITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL UNIVERSITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL UNIVERSITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL AND BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL AND BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL AND BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEMATOLOGIC CANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMATOLOGIC CANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HEMATOLOGIC CANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 348. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY IMMUNO ONCOLOGY ASSAYS MA